Sponsor or institution

Clinical trials and research at Almirall, S.A.

• 8Clinical trials
• 7Countries

Newest trials

All recruiting trials (8)

• LAD328 in adults with hidradenitis suppurativa

  This study tests whether LAD328 works better than placebo for adults with moderate-to-severe hidradenitis suppurativa.

  Recruiting Phase 2 Almirall, S.A. · Warsaw, Masovian Voivodeship · NCT07547813

• Lebrikizumab for adults with nummular eczema

  This study tests whether lebrikizumab can help adults with nummular eczema who don’t respond well to topical steroids.

  Recruiting Phase 3 Almirall, S.A. · Freiburg im Breisgau · NCT07542483

• LAD106 in Healthy Adult Volunteers

  This test gives single and multiple doses of experimental drug LAD106 to healthy adults to see if it is safe, how the body handles it, and whether it triggers immune responses.

  Recruiting Phase 1 Almirall, S.A. · Leiden · NCT07471932

• LAD603 treatment for adults with severe to very severe alopecia areata

  This trial will test whether LAD603 can help adults with severe to very severe alopecia areata regrow scalp hair.

  Recruiting Phase 2 Almirall, S.A. · Omaha, Nebraska · NCT07311564

• LAD191 for adults with moderate-to-severe hidradenitis suppurativa

  This trial will try different doses of LAD191 to see if it reduces lesions and symptoms in adults with moderate-to-severe hidradenitis suppurativa compared with placebo and adalimumab.

  Recruiting Phase 2 Almirall, S.A. · Manises · NCT07151937

• Evaluating the effects of lebrikizumab on well-being in adults with moderate-to-severe atopic dermatitis

  This study is testing how the medication lebrikizumab affects the well-being and skin symptoms of adults with moderate-to-severe atopic dermatitis in everyday settings.

  Recruiting Almirall, S.A. · Aarhus, Denmark · NCT06815380

• Switching to Tildrakizumab for Moderate to Severe Plaque Psoriasis

  This study tests if switching patients with moderate to severe plaque psoriasis to a new medication called tildrakizumab can improve their skin condition and quality of life.

  Recruiting Almirall, S.A. · Graz, Styria · NCT06030076

• Evaluating Tildrakizumab for Genital Psoriasis Treatment

  This study is testing if a new medication called tildrakizumab can help people with genital psoriasis feel better and improve their quality of life.

  Recruiting Almirall, S.A. · Graz, Styria · NCT06029257

Quick answers

How many clinical trials run by Almirall, S.A. are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 7 countries. The most sites are in Austria (2 trials), Poland (1 trial), Denmark (1 trial), United States (1 trial), Spain (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 1: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →